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Introduction
Methicillin-Resistant Staphylococcus aureus (MRSA),
Clostridium difficile (C. Diff) and Vancomycin-Resistant
Enterococci (VRE) are a significant source of HAIs.
Recently, significant attention has been given to com-
munity acquired strains of these infections. However,
HAIs with these pathogens remain a significant cause of
infections and associated costs to the health system.
Objectives
The purpose of this study is to estimate economic bur-
den of MRSA, CDI, and VRE HAIs among inpatients in
US acute care hospitals.
Methods
The economic burden of MRSA, C. Diff, and VRE were
calculated based on incidence rates and costs attributable
to the pathogen rates from the published literature.
Studies included were those that estimated national inci-
dent rates of one or more of the HAIs. Cost estimates
were used from studies that specifically stated direct
costs associated with the HAIs. The median incidence
rate and cost were derived for the base estimate.
Results
The 2010 estimated total number of HAIs attributed to
the three pathogens was 1.325 million and an economic
burden attributable to the pathogens of $13.1 billion.
There were 1.046 million MRSA HAIs, 219,000 C.Diff
HAIs, and 59,000 VRE HAIs. Sensitivity analysis of
the incidence rate revealed that the total number of
HAIs ranged from 844,000 to 1.81 million and the
associated economic burden ranged from $8.46 billion to
$17.73 billion. Sensitivity analysis of the costs ranged
from $9.8 billion to $16.4 billion.
Conclusion
MRSA, C. Diff, and VRE result in significant HAIs and
economic burden in patients hospitalized in US acute
care hospitals. For hospitals to remain profitable, one
important step should be a rigorous analysis of HAIs and
comprehensive preventative programs to reduce their
occurrence. Quality improvement programs to reduce
preventable HAIs such as MRSA, C. Diff, and VRE will
not only improve patient quality, but will increase hospi-
tal profitability by reducing HAIs that are subject to
financial disincentives.
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